Posts

Primary Membranous Nephropathy (PMN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Primary Membranous Nephropathy (PMN) Market Outlook Thelansis’s “Primary Membranous Nephropathy (PMN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Membranous Nephropathy (PMN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China ). Primary Membranous Nephropathy (PMN) Overview Primary membranous nephropathy (PMN) is a rare autoimmune kidney disease in which antibodies target proteins on the kidney’s filtering cells, most often the PLA2R receptor, leading to protein loss, nephrotic syndrome, and, for many patients, gradual decline toward chronic kidney disease. Management has long relied on off-label immunosuppressive r...
Post a Comment
Read more

Relapsed or Refractory Multiple Myeloma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Relapsed or Refractory Multiple Myeloma Market Outlook Thelansis’s “Relapsed or Refractory Multiple Myeloma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Multiple Myeloma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China ). Relapsed or Refractory Multiple Myeloma Overview Relapsed or refractory multiple myeloma (RRMM) describes a blood cancer that returns or stops responding to treatment despite earlier remission, and it remains one of oncology’s most active innovation frontiers, as recurring relapse across treatment lines keeps clinical and commercial need persistently high. Current standard of care r...
Post a Comment
Read more

Locally Advanced or Metastatic HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Locally Advanced or Metastatic HR+/HER2- Breast Cancer Market Outlook Thelansis’s “Locally Advanced or Metastatic HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Locally Advanced or Metastatic HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China ). Locally Advanced or Metastatic HR+/HER2- Breast Cancer Overview Locally advanced or metastatic HR+/HER2- breast cancer is driven by estrogen receptor signaling and represents the most common mBC subtype. Because biomarker discordance and acquired mutations are common, comprehensive molecular profiling (ESR1, PIK3CA, AKT1, PTEN, gBRCA) is ...
Post a Comment
Read more

PRKAG2 Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

PRKAG2 Syndrome Market Outlook Thelansis’s “PRKAG2 Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential PRKAG2 Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China ). PRKAG2 Syndrome Overview PRKAG2 syndrome is a rare, autosomal dominant glycogen storage cardiomyopathy caused by  PRKAG2  mutations. This disrupts the AMP-activated protein kinase (AMPK) energy sensor, driving massive, toxic glycogen accumulation within cardiomyocytes and the cardiac conduction system. Patients present with a hallmark clinical triad: severe cardiac hypertrophy (mimicking sarcomeric hypertrophic cardiomyopathy), ventricular pre...
Post a Comment
Read more

Ischemic Optic Neuropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Ischemic Optic Neuropathy Market Outlook Thelansis’s “Ischemic Optic Neuropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ischemic Optic Neuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China ). Ischemic Optic Neuropathy Overview Ischemic optic neuropathy (ION) is an acute optic nerve infarction. The critical clinical mandate is distinguishing between non-arteritic (NAION) and arteritic etiologies. NAION, the most common form, results from transient hypoperfusion of the short posterior ciliary arteries, typically occurring in structurally crowded optic nerves (“disk at risk”). Key risk factors include hypertension,...
Post a Comment
Read more

Ataxia Telangiectasia (AT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Ataxia Telangiectasia (AT) Market Outlook Thelansis’s “Ataxia Telangiectasia (AT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ataxia Telangiectasia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China ). Ataxia Telangiectasia (AT) Overview Ataxia Telangiectasia is a rare, autosomal recessive multisystem disorder caused by biallelic  ATM  mutations, resulting in profound DNA repair defects and genomic instability. Patients classically present in early childhood with progressive cerebellar ataxia, oculocutaneous telangiectasias, and immunodeficiency, frequently losing ambulatory capacity by adolescence. Because of thei...
Post a Comment
Read more

Global Oral Mucositis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035

Global Oral Mucositis Market Outlook Thelansis’s “Global Oral Mucositis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Oral Mucositis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America ). Global Oral Mucositis Overview Oral mucositis is a painful, often debilitating breakdown of the mouth’s lining that develops as a side effect of chemotherapy, radiation, and stem cell transplantation, frequently forcing interruptions or dose reductions in the cancer treatment causing it and materially affecting nutrition, comfort, and quality of life. Despite decades of clinical attention...
Post a Comment
Read more